GlassScriptPhysician profile
Jarrett B Lea
NPI 1467436725
$1,731.07
in general payments reported to CMS, 2019-2025
23 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $110 · 2022: $31.44 · 2023: $22.40 · 2024: $184 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $303.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $227.28 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $176.27 | 2019-2025 | Breztri |
| Astellas Pharma US INC | $121.96 | 2019-2024 | Veozah |
| Amgen INC. | $111.10 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.78 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $87.80 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $76.61 | 2024-2025 | |
| Abbott Laboratories | $75.54 | 2022-2025 | Freestyle Libre 3, Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $63.41 | 2019-2025 | Trintellix |
| Shire North American Group INC | $60.60 | 2019 | |
| Lilly USA, LLC | $57.16 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $51.37 | 2019-2020 | |
| Exact Sciences Corporation | $31.88 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $30.61 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.93 | 2019-2020 | |
| Allergan, INC. | $26.77 | 2019 | |
| Dexcom, INC. | $20.09 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.05 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.20 | 2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $15.06 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $12.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarrett Lea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.